baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Ascendis Pharma A/S/ US04351P1012 /

2024-05-17 7:47:22 PM	Chg. -1.40	Volume	Bid2024-05-17	Ask-	High	Low
121.50USD	-1.14%	31,415 Turnover: 3.81 mill.	121.42Bid Size: 100	-Ask Size: -	123.03	120.77

GlobeNewswire 05-14 Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™...

GlobeNewswire 05-13 Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparath...

GlobeNewswire 05-13 Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Tr...

GlobeNewswire 05-09 Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with...

GlobeNewswire 05-02 Ascendis Pharma Reports First Quarter 2024 Financial Results

GlobeNewswire 04-25 Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2,...

GlobeNewswire 04-24 United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment o...

GlobeNewswire 04-16 Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr.

GlobeNewswire 03-04 Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024

GlobeNewswire 02-15 Royalty Pharma Reports Q4 and Full Year 2023 Results

GlobeNewswire 02-07 Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results

GlobeNewswire 01-31 Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7...

GlobeNewswire 01-31 Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for ...

GlobeNewswire 01-29 New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitm...

GlobeNewswire 01-09 Er-Kim Announces Exclusive Distribution Agreement with Ascendis Pharma A/S to Commercialize 3 Endocr...

GlobeNewswire 01-08 Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (...

GlobeNewswire 01-07 Ascendis Pharma Introduces Vision 2030

GlobeNewswire 01-04 Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer

GlobeNewswire 2023-12-28 Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 2023-12-20 Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated...

GlobeNewswire 2023-12-19 TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Ph...

GlobeNewswire 2023-12-11 FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with...

GlobeNewswire 2023-11-29 Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan

GlobeNewswire 2023-11-20 Ascendis Pharma Announces European Commission Approval of YORVIPATH® (palopegteriparatide) for the T...

GlobeNewswire 2023-11-15 Ascendis Pharma Resubmits NDA for TransCon™ PTH to the U.S. FDA

Ascendis Pharma A/S/ US04351P1012 /

If you wish to receive reply to your feedback, please provide your email address.